AIRLINK 180.10 Increased By ▲ 3.78 (2.14%)
BOP 13.09 Decreased By ▼ -0.36 (-2.68%)
CNERGY 7.48 Decreased By ▼ -0.01 (-0.13%)
FCCL 45.18 Decreased By ▼ -0.11 (-0.24%)
FFL 16.06 Increased By ▲ 0.84 (5.52%)
FLYNG 27.43 Increased By ▲ 0.43 (1.59%)
HUBC 133.24 Increased By ▲ 0.14 (0.11%)
HUMNL 13.02 Increased By ▲ 0.01 (0.08%)
KEL 4.45 No Change ▼ 0.00 (0%)
KOSM 5.97 Increased By ▲ 0.01 (0.17%)
MLCF 58.81 Increased By ▲ 0.78 (1.34%)
OGDC 218.59 Increased By ▲ 0.31 (0.14%)
PACE 5.87 No Change ▼ 0.00 (0%)
PAEL 42.62 Increased By ▲ 1.00 (2.4%)
PIAHCLA 16.50 Increased By ▲ 0.14 (0.86%)
PIBTL 9.92 Increased By ▲ 0.50 (5.31%)
POWER 11.95 Increased By ▲ 0.07 (0.59%)
PPL 183.08 Decreased By ▼ -1.54 (-0.83%)
PRL 35.33 Increased By ▲ 0.15 (0.43%)
PTC 24.34 Increased By ▲ 0.64 (2.7%)
SEARL 95.82 Increased By ▲ 1.29 (1.36%)
SILK 1.15 Decreased By ▼ -0.02 (-1.71%)
SSGC 37.31 Increased By ▲ 0.11 (0.3%)
SYM 16.08 Decreased By ▼ -0.10 (-0.62%)
TELE 7.88 Increased By ▲ 0.01 (0.13%)
TPLP 10.84 Increased By ▲ 0.10 (0.93%)
TRG 60.94 Decreased By ▼ -0.40 (-0.65%)
WAVESAPP 10.79 Increased By ▲ 0.02 (0.19%)
WTL 1.33 Decreased By ▼ -0.01 (-0.75%)
YOUW 3.77 Increased By ▲ 0.01 (0.27%)
BR100 12,215 Decreased By -29.5 (-0.24%)
BR30 37,439 Increased By 64.4 (0.17%)
KSE100 115,536 Increased By 441.9 (0.38%)
KSE30 35,658 Increased By 47 (0.13%)

India’s Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics, a US-based immunotherapy and targeted oncology company, for $355 million.

The deal is in line with Sun Pharma’s active push in recent years to expand its oncology and immunotherapy portfolio through several acquisitions and collaborations.

Last year, it signed a licensing agreement with Italian-Swiss firm Philogen for its anti-cancer drug Fibromun.

Monday’s transaction, which is expected to be completed in the second quarter of 2025, will add UNLOXCYT, a US FDA-approved treatment for advanced skin cancer, to Sun Pharma’s global franchise.

The deal will be made through an upfront cash payment of $4.10 per common share, a premium of about 66% to Checkpoint’s last close on Friday, the Indian pharma company said in an exchange filing.

Sun Pharma founder to invest $290mn in turbine maker Suzlon

Checkpoint shareholders could also receive up to an additional $0.70 per share in cash, if its cancer immunotherapy cosibelimab secures approval in the EU or key European markets by specific deadlines, as per the deal terms.

Checkpoint’s controlling shareholder Fortress Biotech will receive royalty payments on future sales of cosibelimab for a set period, as per the deal.

Sun Pharma shares were trading 1.2% higher in early trade on Monday after the deal announcement.

Comments

200 characters